Z-521
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Hypophosphatemic Rickets
Conditions
Primary Hypophosphatemic Rickets
Trial Timeline
Sep 1, 2010 → Jul 1, 2013
NCT ID
NCT01237288About Z-521
Z-521 is a phase 3 stage product being developed by Zeria Pharmaceutical for Primary Hypophosphatemic Rickets. The current trial status is completed. This product is registered under clinical trial identifier NCT01237288. Target conditions include Primary Hypophosphatemic Rickets.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01237288 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Hypophosphatemic Rickets